More health workers, stronger systems: Africa’s new ambitious goal - UN News

The World Health Organization (WHO) launched a new five-year strategy for its Hub for Pandemic and Epidemic Intelligence, charting a path towards a world where every country can detect and understand emerging health threats within 24 hours of their appearance by 2030. Strengthening rapid detection is a cornerstone of global health security, helping countries contain outbreaks before they escalate into larger epidemics or spread internationally. The Hub’s strategy aims to equip every country with the capabilities needed to rapidly identify and understand emerging health threats, thus supporting them in developing the systems, capacities and partnerships necessary to prevent outbreaks from escalating into epidemics or pandemics. Speaking at the opening of the World Health Summit in Berlin, in the presence of Germany’s Parliamentary State Secretary at the Federal Ministry of Health, Georg Kippels, WHO Director-General Dr Tedros Adhanom Ghebreyesus reflected on the Hub’s achievements in the five years since its creation. "Five years after its establishment, the WHO Hub for Pandemic and Epidemic Intelligence has become an integral part of the global health security system," he said.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.